Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLOG
- Development stage
- Unknown
- Lead developer
- National Health Research Institutes
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
SLOG is a multi-agent chemotherapy regimen consisting of S-1 (a combination of tegafur, gimeracil, and oteracil), leucovorin (folinic acid), oxaliplatin, and gemcitabine. It is primarily developed and investigated by the Taiwan Cooperative Oncology Group (TCOG) and the National Health Research Institutes (NHRI) for the treatment of advanced gastrointestinal malignancies, particularly pancreatic ductal adenocarcinoma (PDAC) and biliary tract cancers. The regimen is designed to provide a potent combination of antimetabolites and platinum-based agents, often compared to modified FOLFIRINOX (mFOLFIRINOX) in clinical trials to evaluate its efficacy and safety profile as a first-line treatment option. Recent studies have also explored SLOG as a backbone for combination therapies with allogeneic NK cells.
- Other names
- S-1 + leucovorin + oxaliplatin + gemcitabinetegafur + leucovorin + oxaliplatin + gemcitabine
02
Targets
DNA polymerase familyDNATS (Thymidylate synthase)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on SLOG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLOG.